Comment: This is a PEGylated version of recombinant human G-CSF. Pegylation increases circulating half-life. In addition to pegfilgrastim, lipegfilgrastim (Lonquex®) is a glyco-PEGylated long-acting G-CSF, that is an alternative to pegfilgrastim [
1].
Biosimilars: | Name | Trade name | Company | Clinical phase | Indications |
|---|
| pegfilgrastim-jmbd; MYL-1401H | Fulphila | Mylan | Approved (2018 FDA & EMA) | As per reference agent [2] |
| | Pelgraz | Accord | Approved (2018 EMA) | As per reference agent |
| | Pelmeg | Mundipharma (developed by Cinfa Biotech) | Approved (2018 EMA) | As per reference agent |
| | pegfilgrastim Mundipharma | Mundipharma | Approved (2019 EMA) | As per reference agent |
| pegfilgrastim-cbqv; CHS-1701 | Udenyca | ERA Consulting; Coherus BioSciences | Approved (2018 FDA & EMA) | As per reference agent |
| USV pegfilgrastim | Grasustek | Juta Pharma | Approved (2019 EMA) | As per reference agent |
| pegfilgrastim-bmez; LA-EP2006 | Ziextenzo | Sandoz | Approved (2018 EMA, 2019 FDA) | As per reference agent |
| pegfilgrastim-apgf; PF-06881894 | Nyvepria | Pfizer | Approved (2020 FDA) | As per reference agent |
| pegfilgrastim-fpgk; MSB11455 | Stimufend | Fresenius Kabi | Approved (2022 FDA & EMA) | As per reference agent |
| pegfilgrastim-pbbk | Fylnetra | Amneal Pharmaceuticals | Approved (2022 FDA) | As per reference agent |
